Nasdaq · Biotech stocks database
VOGX (Vogenx Inc) stock: $32.50, $482.8M market cap, $0.2M cash, $482.6M EV. Next expected readout: Oct-27. Lead program: Mizagliflozin 5 mg (Postbariatric Hypoglycemia), Phase 2. Data from Fully Diluted's biotech stocks database.
| Cash | $0.2M |
|---|---|
| Debt | $0.0M |
| Net cash | $0.2M |
| Enterprise value | $482.6M |
| Basic shares | 14.9M shares |
| Fully diluted shares | Not disclosed |
| Fully diluted market cap | Not disclosed |
| Cash per share | $0.02 |
Cash figures as of 2026-03-31. Database snapshot: 2026-09-21.
Loading VOGX daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Nov 12 - Dec 24 | Mizagliflozin 5 mg | Phase 2 | Postbariatric Hypoglycemia | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.